H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on CYBN stock, giving a Buy rating on August 14.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors including Cybin’s strategic advancements and financial positioning. The company has secured fresh capital and regulatory clearances, setting the stage for significant developments in the next 12 months. Key catalysts include the completion of enrollment for CYB004’s Phase 2 trial in generalized anxiety disorder by August 2025, with top-line data expected in the second half of 2025, and the ongoing progress of the CYB003 Phase 3 program, which has received clinical trial application approvals in Europe and the UK, facilitating site initiations across multiple regions.
Additionally, Cybin’s operational strategies, such as commercial-scale manufacturing and clinic-network partnerships, alongside a substantial convertible debenture facility, extend its financial runway beyond 2026. The company’s promising clinical data, particularly the durability signal from CYB003 and its Breakthrough Therapy Designation, along with CYB004’s short-acting profile, position Cybin to offer innovative treatments for mood and anxiety disorders. These elements collectively underpin Trucchio’s confidence in Cybin’s potential, reinforcing his Buy rating.
In another report released on August 14, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.